Post-treatment imaging of musculoskeletal sarcoma remains challenging, but newer imaging techniques are improving our ability to recognize both local and distant recurrence and accurately distinguish local recurrence from post-treatment change. We review recent advances in dynamic contrast-enhanced magnetic resonance imaging, diffusion-weighted magnetic resonance imaging with apparent diffusion coefficient mapping and positron emission tomography/computed tomography in the post-treatment follow-up of musculoskeletal sarcoma. We also describe our multidisciplinary sarcoma team approach to patient care and the essential role of the radiologist in the clinical follow-up scheme.
American Cancer SocietyCancer Facts & Figures 20142014American Cancer SocietyAtlanta, GA
2.
DoyleL.A.Sarcoma classification: an update based on the 2013 World Health Organization Classification of Tumors of Soft Tissue and BoneCancer2014; 120:1763–1774.
3.
FletcherC.D.The evolving classification of soft tissue tumours - an update based on the new 2013 WHO classificationHistopathology2014; 64:2–11.
4.
FletcherC.D.M.RydholmA.SingerS.Soft tissue tumours: epidemiology, clinical features, histopathological typing and gradingFletcherC.D.M.BridgeJ.HogendoornP.C.W.WHO Classification of Tumours of Soft Tissue and Bone2013IARC PressLyon, France14–16.
5.
AllisonD.C.CarneyS.C.AhlmannE.R.A meta-analysis of osteosarcoma outcomes in the modern medical eraSarcoma20122012704872
6.
AroraR.S.AlstonR.D.EdenT.O.The contrasting age-incidence patterns of bone tumours in teenagers and young adults: Implications for aetiologyInt J Cancer2012; 131:1678–1685.
7.
MatushanskyI.TaubR.N.Adjuvant chemotherapy in 2011 for patients with soft-tissue sarcomaNat Rev Clin Oncol2011; 8:434–438.
8.
ToroJ.R.TravisL.B.WuH.J.Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: an analysis of 26,758 casesInt J Cancer2006; 119:2922–2930.
9.
HowladerN.NooneA.M.KrapchoM.Cancer Statistics Review, 1975–20112013National Cancer InstituteBethesda
10.
CormierJ.N.PollockR.E.Soft tissue sarcomasCA Cancer J Clin2004; 54:94–109.
11.
FerrariS.BriccoliA.MercuriM.Late relapse in osteosarcomaJ Pediatr Hematol Oncol2006; 28:418–422.
12.
HaubenE.I.BielackS.GrimerR.Clinico-histologic parameters of osteosarcoma patients with late relapseEur J Cancer2006; 42:460–466.
13.
StraussS.J.McTiernanA.WhelanJ.S.Late relapse of osteosarcoma: implications for follow-up and screeningPediatr Blood Cancer2004; 43:692–697.
14.
ZogaA.C.WeissmanB.N.KransdorfM.J.Expert Panel on Musculoskeletal ImagingACR Appropriateness Criteria. Soft tissue masses2012Reston: American College of Radiology
15.
QureshiY.A.HuddyJ.R.MillerJ.D.Unplanned excision of soft tissue sarcoma results in increased rates of local recurrence despite full further oncological treatmentAnn Surg Oncol2012; 19:871–877.
16.
KransdorfM.J.MurpheyM.D.Imaging of soft tissue massesKransdorfM.J.MurpheyM.D.Imaging of Soft Tissue Tumors 3rd ed 2014Lippincitt Williams WilkinsPhiladelphia, PA39–93.
17.
GarnerH.W.KransdorfM.J.BancroftL.W.Benign and malignant soft-tissue tumours: posttreatment MR imagingRadiographics2009; 29:119–134.
18.
GarnerH.W.KransdorfM.J.PetersonJ.J.Posttherapy imaging of musculoskeletal neoplasmsRadiol Clin North Am2011; 49:1307–1323.
19.
PotterB.K.HwangP.F.ForsbergJ.A.Impact of margin status and local recurrence on soft-tissue sarcoma outcomesJ Bone Joint Surg Am952013e151
20.
ErlemannR.SciukJ.BosseA.Response of osteosarcoma and Ewing sarcoma to preoperative chemotherapy: assessment with dynamic and static MR imaging and skeletal scintigraphyRadiology1990; 175:791–796.
21.
SanchezR.B.QuinnS.F.WallingA.Musculoskeletal neoplasms after intraarterial chemotherapy: correlation of MR images with pathologic specimensRadiology1990; 174:237–240.
22.
GenovesiD.Ausili CefaroG.TrignaniM.Interobserver variability of clinical target volume delineation in soft-tissue sarcomasCancer Radiother2014; 18:89–96.
23.
RobergeD.SkameneT.NahalA.Radiological and pathological response following pre-operative radiotherapy for soft-tissue sarcomaRadiother Oncol2010; 97:404–407.
24.
le GrangeF.CassoniA.M.SeddonB.M.Tumour volume changes following pre-operative radiotherapy in borderline resectable limb and trunk soft tissue sarcomaEur J Surg Oncol2014; 40:394–401.
25.
MikiY.NganS.ClarkJ.C.AkiyamaT.ChoongP.F.The significance of size change of soft tissue sarcoma during preoperative radiotherapyEur J Surg Oncol2010; 36:678–683.
26.
FayadL.M.JacobsM.A.WangX.Musculoskeletal tumours: how to use anatomic, functional, and metabolic MR techniquesRadiology2012; 265:340–356.
27.
FayadL.M.SalibiN.WangX.Quantification of muscle choline concentrations by proton MR spectroscopy at 3 T: technical feasibilityAJR Am J Roentgenol2010; 194:W73–W79.
28.
DykeJ.P.PanicekD.M.HealeyJ.H.Osteogenic and Ewing sarcomas: estimation of necrotic fraction during induction chemotherapy with dynamic contrast-enhanced MR imagingRadiology2003; 228:271–278.
29.
van RijswijkC.S.GeirnaerdtM.J.HogendoornP.C.Dynamic contrast-enhanced MR imaging in monitoring response to isolated limb perfusion in high-grade soft tissue sarcoma: initial resultsEur Radiol2003; 13:1849–1858.
30.
LandaJ.SchwartzL.H.Contemporary imaging in sarcomaOncologist2009; 14:1021–1038.
31.
MeyerJ.M.PerlewitzK.S.HaydenJ.B.Phase I trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlatesClin Cancer Res2013; 19:6902–6911.
32.
FayadL.M.MugeraC.SoldatosT.Technical innovation in dynamic contrast-enhanced magnetic resonance imaging of musculoskeletal tumours: an MR angiographic sequence using a sparse k-space sampling strategySkeletal Radiol2013; 42:993–1000.
33.
Del GrandeF.SubhawongT.WeberK.Detection of soft-tissue sarcoma recurrence: added value of functional MR imaging techniques at 3.0 TRadiology2014; 271:499–511.
34.
MarcusC.D.Ladam-MarcusV.CucuC.Imaging techniques to evaluate the response to treatment in oncology: current standards and perspectivesCrit Rev Oncol Hematol2009; 72:217–238.
35.
BajpaiJ.GamnagattiS.KumarR.Role of MRI in osteosarcoma for evaluation and prediction of chemotherapy response: correlation with histological necrosisPediatr Radiol2011; 41:441–450.
36.
BauninC.SchmidtG.BaumstarckK.Value of diffusion-weighted images in differentiating mid-course responders to chemotherapy for osteosarcoma compared to the histological response: preliminary resultsSkeletal Radiol2012; 41:1141–1149.
37.
ByunB.H.KongC.B.LimI.Combination of 18F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: preliminary results in osteosarcomaJ Nucl Med2013; 54:1053–1059.
38.
DudeckO.ZeileM.PinkD.Diffusion-weighted magnetic resonance imaging allows monitoring of anticancer treatment effects in patients with soft-tissue sarcomasJ Magn Reson Imaging2008; 27:1109–1113.
39.
EinarsdottirH.KarlssonM.WejdeJ.Diffusion-weighted MRI of soft tissue tumoursEur Radiol2004; 14:959–963.
40.
HayashidaY.YakushijiT.AwaiK.Monitoring therapeutic responses of primary bone tumours by diffusion-weighted image: Initial resultsEur Radiol2006; 16:2637–2643.
41.
OkaK.YakushijiT.SatoH.The value of diffusion-weighted imaging for monitoring the chemotherapeutic response of osteosarcoma: a comparison between average apparent diffusion coefficient and minimum apparent diffusion coefficientSkeletal Radiol2010; 39:141–146.
42.
UhlM.SaueressigU.KoehlerG.Evaluation of tumour necrosis during chemotherapy with diffusion-weighted MR imaging: preliminary results in osteosarcomasPediatr Radiol2006; 36:1306–1311.
43.
UhlM.SaueressigU.van BuirenM.Osteosarcoma: preliminary results of in vivo assessment of tumour necrosis after chemotherapy with diffusion- and perfusion-weighted magnetic resonance imagingInvest Radiol2006; 41:618–623.
44.
WangX.JacobsM.A.FayadL.Therapeutic response in musculoskeletal soft tissue sarcomas: evaluation by MRINMR Biomed2011; 24:750–763.
45.
BaurA.HuberA.ArbogastS.Diffusion-weighted imaging of tumour recurrencies and posttherapeutical soft-tissue changes in humansEur Radiol2001; 11:828–833.
46.
SubhawongT.K.JacobsM.A.FayadL.M.Insights into quantitative diffusion-weighted MRI for musculoskeletal tumour imagingAJR Am J Roentgenol2014; 203:560–572.
47.
BenzM.R.EvilevitchV.Allen-AuerbachM.S.Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumoursJ Nucl Med2008; 49:1038–1046.
48.
BenzM.R.TchekmedyianN.EilberF.C.Utilization of positron emission tomography in the management of patients with sarcomaCurr Opin Oncol2009; 21:345–351.
49.
CaldarellaC.SalsanoM.IsgroM.A.The role of fluorine-18-fluorodeoxyglucose positron emission tomography in assessing the response to neoadjuvant treatment in patients with osteosarcomaInt J Mol Imaging20122012870301
50.
PiperkovaE.MikhaeilM.MousaviA.Impact of PET and CT in PET/CT studies for staging and evaluating treatment response in bone and soft tissue sarcomasClin Nucl Med2009; 34:146–150.
51.
HongtaoL.HuiZ.BingshunW.18F-FDG positron emission tomography for the assessment of histological response to neoadjuvant chemotherapy in osteosarcomas: a meta-analysisSurg Oncol2012; 21:e165–e170.
52.
EaryJ.F.ConradE.U.O'SullivanJ.Sarcoma mid-therapy [F-18]fluorodeoxyglucose positron emission tomography (FDG PET) and patient outcomeJ Bone Joint Surg Am2014; 96:152–158.
53.
QuartuccioN.TregliaG.SalsanoM.The role of Fluorine-18-Fluorodeoxyglucose positron emission tomography in staging and restaging of patients with osteosarcomaRadiol Oncol2013; 47:97–102.
54.
AljubranA.H.GriffinA.PintilieM.Osteosarcoma in adolescents and adults: survival analysis with and without lung metastasesAnn Oncol2009; 20:1136–1141.
55.
BacciG.LonghiA.VersariM.Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institutionCancer2006; 106:1154–1161.
56.
CoindreJ.M.TerrierP.BuiN.B.Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma GroupJ Clin Oncol1996; 14:869–877.
57.
PistersP.W.LeungD.H.WoodruffJ.Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremitiesJ Clin Oncol1996; 14:1679–1689.
58.
van der GraafW.T.BlayJ.Y.ChawlaS.P.Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trialLancet2012; 379:1879–1886.
59.
van der GraafW.T.GelderblomH.New systemic therapy options for advanced sarcomasCurr Treat Options Oncol2012; 13:306–317.
60.
TregliaG.SalsanoM.StefanelliA.Diagnostic accuracy of (1)(8)F-FDG-PET and PET/CT in patients with Ewing sarcoma family tumours: a systematic review and a meta-analysisSkeletal Radiol2012; 41:249–256.
61.
IagaruA.ChawlaS.MenendezL.18F-FDG PET and PET/CT for detection of pulmonary metastases from musculoskeletal sarcomasNucl Med Commun2006; 27:795–802.
62.
IagaruA.QuonA.McDougallI.R.F-18 FDG PET/CT evaluation of osseous and soft tissue sarcomasClin Nucl Med2006; 31:754–760.
63.
FranziusC.JuergensK.U.PET/CT in paediatric oncology: indications and pitfallsPediatr Radiol39Suppl 32009446–449.
64.
BesticJ.M.PetersonJ.J.BancroftL.W.Pediatric FDG PET/CT: Physiologic uptake, normal variants, and benign conditions [corrected]Radiographics2009; 29:1487–1500.
65.
FitzgeraldJ.J.RobertsC.C.DaffnerR.H.Follow-Up of Malignant or Aggressive Musculoskeletal Tumors2011American College of RadiologyReston, VA
66.
PatelS.R.ZagarsG.K.PistersP.W.The follow-up of adult soft-tissue sarcomasSemin Oncol2003; 30:413–416.
67.
ChouY.S.LiuC.Y.ChenW.M.Follow-up after primary treatment of soft tissue sarcoma of extremities: impact of frequency of follow-up imaging on disease-specific survivalJ Surg Oncol2012; 106:155–161.
